OncoSec Medical Incorporated (ONCS): Price and Financial Metrics


OncoSec Medical Incorporated (ONCS): $0.77

0.03 (+4.05%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add ONCS to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

ONCS Stock Price Chart Interactive Chart >

Price chart for ONCS

ONCS Price/Volume Stats

Current price $0.77 52-week high $4.25
Prev. close $0.74 52-week low $0.67
Day low $0.73 Volume 36,200
Day high $0.78 Avg. volume 110,497
50-day MA $0.96 Dividend yield N/A
200-day MA $1.37 Market Cap 30.30M

OncoSec Medical Incorporated (ONCS) Company Bio


OncoSec Medical Inc. provides biomedical services. The Company focuses on commercializing therapeutic oncology products. OncoSec Medical offers patients with alternative treatments to existing therapies to treat cancerous tumors and cancerous cells.


ONCS Latest News Stream


Event/Time News Detail
Loading, please wait...

ONCS Latest Social Stream


Loading social stream, please wait...

View Full ONCS Social Stream

Latest ONCS News From Around the Web

Below are the latest news stories about ONCOSEC MEDICAL Inc that investors may wish to consider to help them evaluate ONCS as an investment opportunity.

OncoSec appoints new finance chief

OncoSec Medical Incorporated (ONCS) has appointed George Chi as Chief Financial Officer. Mr

Seeking Alpha | February 23, 2022

OncoSec Announces Appointment of George Chi as Chief Financial Officer

OncoSec Medical Incorporated (NASDAQ: ONCS) (the "Company" or "OncoSec"), a clinical-stage biotechnology company focused on developing intratumoral immunotherapies to stimulate the body's immune system to target and attack cancer, today announced the appointment of George Chi as Chief Financial Officer.

Yahoo | February 22, 2022

OncoSec Announces Changes to its Board of Directors

PENNINGTON, N.J. and SAN DIEGO , Dec. 17, 2021 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ: ONCS ) (the "Company" or "OncoSec"), a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body''s immune system to target and attack cancer, today announced that Margaret Dalesandro , Ph.D., Chair of the Board of Directors and member of the Leadership Committee, has resigned from the Board of Directors and the Leadership Committee, effective immediately, and Dr. Linda Shi , M.D., Ph.D., has been added to the OncoSec Board of Directors and appointed Chair. Kevin Smith remarked, "On behalf of the Board of Directors, we are grateful to Margaret for her leadership, expert guidance, and commitment to the company, particularl...

Benzinga | December 17, 2021

OncoSec Medical (NASDAQ:ONCS) Releases Quarterly Earnings Results

OncoSec Medical (NASDAQ:ONCS) released its quarterly earnings results on Tuesday. The biotechnology company reported ($0.25) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.37) by $0.12, Fidelity Earnings reports. Shares of ONCS traded up $0.01 during mid-day trading on Thursday, hitting $1.23. 4,172 shares of the company traded hands, compared to its []

Dakota Financial News | December 16, 2021

OncoSec Medical (NASDAQ:ONCS) Announces Earnings Results

OncoSec Medical (NASDAQ:ONCS) released its quarterly earnings results on Tuesday. The biotechnology company reported ($0.25) EPS for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.12, Fidelity Earnings reports. ONCS traded up $0.02 on Thursday, hitting $1.24. The company had a trading volume of 3,923 shares, compared to its average volume of 625,943. The […]

Dakota Financial News | December 16, 2021

Read More 'ONCS' Stories Here

ONCS Price Returns

1-mo -4.94%
3-mo N/A
6-mo -42.75%
1-year -80.56%
3-year -70.04%
5-year -91.63%
YTD -19.76%
2021 -85.12%
2020 256.35%
2019 -71.72%
2018 -60.62%
2017 32.11%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.903 seconds.